D.ap wrote:So CT Chest W/contrast
Comparison October 31,2016 to January 24,2017
Lungs and airways : innumerable bilateral pulmonary nodules noted. There is been significant improvement in size of lesions compared with previous study . Multiple lesicions are resolved. Left upper lobe pulmonary nodule on image #23 measures 0.8cm previously 2cm. One of the left lower lobe pulmonary masses measures 1.9cm previously 5.4cm. A dominant right lower lobe mass measures 2.7cm previously 6.3cm. There is stable scarring in both lower lobes
Pleura: unremarkable . No effusions or pneumothorax
Vessels : unremarkable
Heart: normal size. No pericardial effusion
Lymph Nodes: no significant hilar, mediastinal or aillary lymphadenopathy .
Bones and chest wall: unremarkable .
Wanted to remind you all how very very far we’ve come in our journey , from 2016–
June 24, 2019 compared to April 12, 2019
Chest ct and abdomen and pelvis study-
1. Heart remains normal size
2. Mediastinum and pulmonary hula: no adenopathy
3. Lungs and pleura: No significant change in several scattered pulmonary modules . Reference module in right lower lobe again measures 0.6cm. A left lower lobe nodule measures 0.6cm and is unchanged . Partially calcified right lower lobe nodule inferiority is unchanged .
NO NEW NODULES ARE SEEN. Extensive pleural scarring in the lung bases is again noted. No pleural effusion.
Abdomen and pelvis findings :
1.
Liver and spleen: Hepatic metastases are again noted. The largest lesion now (the bland (embolized ) measures 4.8cm x3.5cm compared to 5.5 x3.5 cm previously . The segment 4 lesion is minimally decreased in size 3.7 x 2.1cm compared previously to 3.9 x 2.6cm. No new low density lesions are seen. A tiny segment 8 low density lesion is unchanged and may represent a small cyst on image 90 series 2. Spleen unremarkable
2. Adrenal glands and kidneys : unremarkable
3.Pancreas and retroperiotineum : pancreases unremarkable .
Impression
Chest
1. Stable scattered pulmonary metastases . No new pulmonary nodules.
2. No thoracic adenopathy.
Abdomen and pelvis
1. Decrease in size of hepatic metastases. No new hepatic metastases.
2. No abdominal or pelvic adenopathy.